USA - engelsk - NLM (National Library of Medicine)

acetris health, llc - carvedilol (unii: 0k47ul67f2) (carvedilol - unii:0k47ul67f2) - carvedilol 3.125 mg - carvedilol tablets are indicated for the treatment of mild-to-severe chronic heart failure of ischemic or cardiomyopathic origin, usually in addition to diuretics, ace inhibitors, and digitalis, to increase survival and, also, to reduce the risk of hospitalization [see drug interactions (7.4) and clinical studies (14.1)]. carvedilol tablets are indicated to reduce cardiovascular mortality in clinically stable patients who have survived the acute phase of a myocardial infarction and have a left ventricular ejection fraction of less than or equal to 40% (with or without symptomatic heart failure) [see clinical studies (14.2)] . carvedilol tablets are indicated for the management of essential hypertension [see clinical studies (14.3, 14.4)] . it can be used alone or in combination with other antihypertensive agents, especially thiazide-type diuretics [see drug interactions (7.2)] . - carvedilol tablets are contraindicated in the following conditions: - bronchial asthma or related bronchospastic conditions. death

USA - engelsk - NLM (National Library of Medicine)

ncs healthcare of ky, inc dba vangard labs - carvedilol (unii: 0k47ul67f2) (carvedilol - unii:0k47ul67f2) - carvedilol 3.125 mg - carvedilol is indicated to reduce cardiovascular mortality in clinically stable patients who have survived the acute phase of a myocardial infarction and have a left ventricular ejection fraction of ≤ 40% (with or without symptomatic heart failure) [ see clinical studies(14.1) ] . carvedilol is indicated for the management of essential hypertension [ see clinical studies (14.2, 14.3)]. it can be used alone or in combination with other antihypertensive agents, especially thiazide-type diuretics [see  drug interactions (7.2) ]. carvedilol is contraindicated in the following conditions: - bronchial asthma or related bronchospastic conditions. deaths from status asthmaticus have been reported following single doses of carvedilol - second- or third-degree av block - sick sinus syndrome - severe bradycardia (unless a permanent pacemaker is in place) - patients with cardiogenic shock or who have decompensated heart failure requiring the use of intravenous inotropic therapy. such patients should first be weaned fro

USA - engelsk - NLM (National Library of Medicine)

h.j. harkins company, inc. - carvedilol (unii: 0k47ul67f2) (carvedilol - unii:0k47ul67f2) - carvedilol 6.25 mg - carvedilol tablets are indicated to reduce cardiovascular mortality in clinically stable patients who have survived the acute phase of a myocardial infarction and have a left ventricular ejection fraction of ≤40% (with or without symptomatic heart failure) [see clinical studies (14.1)]. carvedilol tablets are indicated for the management of essential hypertension [see clinical studies (14.2)]. it can be used alone or in combination with other antihypertensive agents, especially thiazide-type diuretics [see drug interactions (7.2)]. carvedilol tablets are contraindicated in the following conditions: - bronchial asthma or related bronchospastic conditions. deaths from status asthmaticus have been reported following single doses of carvedilol tablets. - second- or third-degree av block - sick sinus syndrome - severe bradycardia (unless a permanent pacemaker is in place) - patients with cardiogenic shock or who have decompensated heart failure requiring the use of intravenous inotropic therapy. such patients sho

Australia - engelsk - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - carvedilol, quantity: 25 mg - tablet, film coated - excipient ingredients: crospovidone; magnesium stearate; povidone; sucrose; lactose monohydrate; titanium dioxide; macrogol 400; colloidal anhydrous silica; polysorbate 80; hypromellose - carvedilol is indicated for the treatment of hypertension. data have not been provided to support the use of this drug in renovascular disease.,carvedilol is indicated for the treatment of patients with symptomatic mild to severe (nyha class ii - iv) congestive heart failure (chf) as an adjunct to conventional treatments (e.g. diuretics, digoxin, ace inhibitors and vasodilators).

Australia - engelsk - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - carvedilol, quantity: 12.5 mg - tablet, film coated - excipient ingredients: crospovidone; lactose monohydrate; titanium dioxide; macrogol 400; povidone; colloidal anhydrous silica; sucrose; hypromellose; magnesium stearate; polysorbate 80 - carvedilol is indicated for the treatment of hypertension. data have not been provided to support the use of this drug in renovascular disease.,carvedilol is indicated for the treatment of patients with symptomatic mild to severe (nyha class ii - iv) congestive heart failure (chf) as an adjunct to conventional treatments (e.g. diuretics, digoxin, ace inhibitors and vasodilators).

Australia - engelsk - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - carvedilol, quantity: 6.25 mg - tablet, film coated - excipient ingredients: lactose monohydrate; crospovidone; povidone; sucrose; polysorbate 80; magnesium stearate; titanium dioxide; hypromellose; macrogol 400; colloidal anhydrous silica - carvedilol is indicated for the treatment of hypertension. data have not been provided to support the use of this drug in renovascular disease.,carvedilol is indicated for the treatment of patients with symptomatic mild to severe (nyha class ii - iv) congestive heart failure (chf) as an adjunct to conventional treatments (e.g. diuretics, digoxin, ace inhibitors and vasodilators).

Australia - engelsk - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - carvedilol, quantity: 25 mg - tablet, film coated - excipient ingredients: lactose monohydrate; povidone; titanium dioxide; magnesium stearate; hypromellose; polysorbate 80; colloidal anhydrous silica; sucrose; crospovidone; macrogol 400 - carvedilol is indicated for the treatment of hypertension. data have not been provided to support the use of this drug in renovascular disease.,carvedilol is indicated for the treatment of patients with symptomatic mild to severe (nyha class ii - iv) congestive heart failure (chf) as an adjunct to conventional treatments (e.g. diuretics, digoxin, ace inhibitors and vasodilators).

Australia - engelsk - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - carvedilol, quantity: 3.125 mg - tablet, film coated - excipient ingredients: povidone; lactose monohydrate; macrogol 400; magnesium stearate; titanium dioxide; polysorbate 80; hypromellose; crospovidone; sucrose; colloidal anhydrous silica - carvedilol is indicated for the treatment of hypertension. data have not been provided to support the use of this drug in renovascular disease.,carvedilol is indicated for the treatment of patients with symptomatic mild to severe (nyha class ii - iv) congestive heart failure (chf) as an adjunct to conventional treatments (e.g. diuretics, digoxin, ace inhibitors and vasodilators).

Australia - engelsk - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - carvedilol, quantity: 6.25 mg - tablet, film coated - excipient ingredients: lactose monohydrate; hypromellose; magnesium stearate; povidone; macrogol 400; crospovidone; polysorbate 80; titanium dioxide; colloidal anhydrous silica; sucrose - carvedilol is indicated for the treatment of hypertension. data have not been provided to support the use of this drug in renovascular disease.,carvedilol is indicated for the treatment of patients with symptomatic mild to severe (nyha class ii - iv) congestive heart failure (chf) as an adjunct to conventional treatments (e.g. diuretics, digoxin, ace inhibitors and vasodilators).

Australia - engelsk - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - carvedilol, quantity: 3.125 mg - tablet, film coated - excipient ingredients: magnesium stearate; macrogol 400; crospovidone; povidone; titanium dioxide; colloidal anhydrous silica; sucrose; polysorbate 80; lactose monohydrate; hypromellose - carvedilol is indicated for the treatment of hypertension. data have not been provided to support the use of this drug in renovascular disease.,carvedilol is indicated for the treatment of patients with symptomatic mild to severe (nyha class ii - iv) congestive heart failure (chf) as an adjunct to conventional treatments (e.g. diuretics, digoxin, ace inhibitors and vasodilators).